Be the most informed person in the room with Newsy's free e-newsletter

View our privacy policy:

Martin Shkreli Is At It Again, Refuses To Lower Price Of $750 Drug

The Turing Pharmaceuticals CEO promised to lower the drug price after hiking it up when his company acquired it. But it seems that isn't happening.

Remember Martin Shkreli, arguably the most hated man in pharmaceuticals for raising the cost of a drug HIV patients regularly take by 5,000 percent? Well, he's getting some very unwanted attention again.

Shkreli is the Turing Pharmaceuticals CEO who inflated the cost of the parasite-fighting and lifesaving drug Daraprim from $13.50 to $750. 

Patients, the medical community and the media blasted Shkreli for the move, and eventually he did say he'd reverse the price increase.

But on Wednesday his company said in a press release that it would drop prices by 50 percent for hospitals, create smaller bottles with 30 pills and provide free starter packs in 2016. The company also said, "We pledge that no patient needing Daraprim will ever be denied access." 

Sounds nice, right? Well, these changes might only affect bulk buys, since it seems as if the $750 price per pill is unchanged. 

Shkreli previously said the company needed to increase the pill's price so it could do studies to improve the drug. But critics have questioned his company's ability to do sound scientific research.

Some presidential hopefuls have even used Shkreli and Turing as a part of their platforms for health care or a conversation about how they could regulate the pharmaceutical industry to avoid price hikes like these in the future.

This video includes an image from the U.S. National Library of Medicine.

Featured Stories
The White House

How The White House Prepares For The Next President

A performer riding an elephant.

'The Greatest Show On Earth' Is Ending

French President Francois Hollande addressing conference on peace in the Middle East

France Hosts Israel-Palestine Peace Talks Without Israel Or Palestine

Want to see more stories like this?
Like Newsy on Facebook for More Medicine Coverage